Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.58 |
| ▸ | CASP1 | P29466 | 5/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10565196 | 1.00 | FOLH1 (0.58) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL2921260 | 0.93 | FOLH1 (0.59) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL7624700 | 0.93 | FOLH1 (0.59) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL677997 | 0.93 | FOLH1 (0.59) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL11059124 | 0.90 | MME (0.52) | FOLH1CASP1MMEECE1CTSK | |
| SCHEMBL221391 | 0.90 | KYNU (0.60) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL6259518 | 0.90 | KYNU (0.60) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL2777678 | 0.90 | KYNU (0.60) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL910423 | 0.90 | FOLH1 (0.70) | FOLH1CASP1MMEECE1 | |
| SCHEMBL910233 | 0.90 | FOLH1 (0.70) | FOLH1CASP1MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234508-A1 | Process for the Preparation of N(5)-Ethylglutamine | DONGBU FINE CHEMICALS CO., LTD (KR) | 2008-09-25 | — | — | US | disclosed |
| WO-2006123909-A1 | PROCESS FOR THE PREPARATION OF N(5)-ETHYLGLUTAMINE | DONGBU FINE CHEMICALS CO., LTD. (KR) | 2006-11-23 | — | — | WO | disclosed |
| EP-1051655-B1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| EP-1051655-A4 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-20010016731-A1 | Methods and apparatus for accelerated orthokeratology | DEVORE DALE (US) | 2001-08-23 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| US-6161544-A | Methods for accelerated orthokeratology | KERATOFORM, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1994020454-A1 | NEW DERIVATIVES OF GLUTAMIC AND ASPARTIC ACIDS, A METHOD OF PREPARING THEM, AND THEIR USE AS DRUGS FOR ENHANCING MEMORY AND LEARNING | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1994-09-15 | — | — | WO | disclosed |
| EP-0436612-A4 | AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER | — | 1992-05-20 | — | — | EP | disclosed |
| EP-0436612-A1 | AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1991-07-17 | — | — | EP | disclosed |
| WO-1990003399-A1 | AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1990-04-05 | — | — | WO | disclosed |
| US-4883864-A | COUPLED AND FREE AMINE GROUPS CAPPED WITH UREA OR AMIDE GROUPS, EYE SURGERY | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-11-28 | — | — | US | disclosed |
| US-4870162-A | COUPLING WITH PROTEIN, ANTITUMOR | OMNICHEM (BE) | 1989-09-26 | — | — | US | disclosed |
| US-4851513-A | Viscoelastic collagen solution for opthalmic use and method of preparation | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| US-4713446-A | COLLAGEN COUPLED TO CARBONYL OR SULFONYL GROUPS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-12-15 | — | — | US | disclosed |
| US-4661512-A | Adamantanamine derivatives, processes for their preparation and drugs in which they are present | S. A. PANMEDICA (FR) | 1987-04-28 | — | — | US | disclosed |
| EP-0214853-A2 | Viscoelastic collagen solution for ophthalmic use and method of preparation | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234508-A1 | Process for the Preparation of N(5)-Ethylglutamine | GLUL, PGA5, GRIK5 | FOLH1 24/4885CASP1 3543/4885MME 385/4885 |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | FOLH1 3887/4885CASP1 554/4885MME 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.